



## New white paper series presents recent findings and information on the use of proton therapy in oncology

IBA strives to support radiotherapy and oncology experts with publication of white paper series featuring pertinent information on the clinical application of proton therapy

**Louvain-la-Neuve, Belgium, October 16, 2015** – Today, IBA (Ion Beam Applications S.A., Euronext), the world's leading provider of proton therapy solutions for the treatment of cancer, announces the publication of the first two installments in its white paper series on proton therapy in oncology. The series offers a compilation of information on current practice, opportunities and challenges of proton therapy in oncology. In addition to providing a general introduction to proton therapy, the white papers will present an overview of indication-specific data and findings, with the primary purpose of facilitating access to the most relevant information on the use of proton therapy for stakeholders in radiation oncology worldwide.

IBA is publishing two installments today: the first offers a general introduction to proton therapy, and the second provides an overview of the literature on proton therapy for pediatric cancer. More than 10 indication-specific white papers will follow, outlining the benefits of proton therapy for a range of indications, for example skull base malignancies, ocular tumors, lung cancer, and Hodgkin lymphoma.

The amount of clinical data on proton therapy is increasing rapidly, making it a challenge to keep up with new findings and advancements. IBA has always fostered a culture of collaboration and information sharing, and the company has leveraged its day-to-day involvement with experienced clinical teams from proton therapy centers worldwide to assemble information on recent developments and data.

The series is conceived as a work-in-progress, allowing for updates and expansions along the way, as clinical insights evolve and technological innovations lift proton therapy to the next level. The general introduction details the history, general relevance, patient selection policy, clinical trial status, future developments, cost-effectiveness, health economics and the current availability of proton radiation therapy. The first indication and each following installment outline the indication-specific benefits of proton radiation therapy and offer dosimetric comparisons, a review of the literature on clinical outcomes and an overview of ongoing studies. Key scientific journals were consulted to obtain this information, and a field expert's perspective is included.

**Michel Closset, Clinical Director at IBA, stated:** "Even though the clinical application of proton therapy is a medical field in full evolution, we have worked to ensure that these white papers are as complete, correct and up-to-date as possible. Our hope is that this information will deepen and advance radiotherapy and oncology experts' understanding of proton therapy cancer treatment, so that we can continue to make proton therapy accessible to more patients worldwide."

**Olivier Legrain, IBA's CEO, commented:** "The IBA team firmly believes in the benefits and the extraordinary promise of proton therapy for patients and society. Our primary goal is to make this radiation therapy modality available for anyone who needs it, and we have learned from experience that the best way to do this is through collaboration and sharing information."

-----END-----



## **About Proton Therapy**

Proton Therapy is considered the most advanced and targeted cancer radiotherapy treatment due to its superior dose distribution and fewer side effects. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, sparing healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby improving patient outcomes and quality of life. Today, more than half of all proton therapy clinical facilities worldwide are equipped with IBA systems. This includes 18 proton therapy centers currently in operation and 16 additional centers under development.

While proton therapy today represents less than 1% of radiotherapy treatments, studies estimate that more than 17% of patients treated by radiotherapy would benefit from being treated by this technique.

## **About IBA**

IBA (Ion Beam Applications S.A.) is a global medical technology company focused on bringing integrated and innovative solutions for the diagnosis and treatment of cancer. The company is the worldwide technology leader in the field of proton therapy, the most advanced form of radiation therapy available today. IBA's proton therapy solutions are flexible and adaptable, allowing customers to choose from universal full-scale proton therapy centers as well as compact, single room systems. In addition, IBA also has a radiation dosimetry business and develops particle accelerators for the medical world and industry.

Headquartered in Belgium and employing about 1100 people worldwide, IBA has installed systems across the world, from Europe and the US to emerging markets. IBA is listed on the panEuropean stock exchange EURONEXT. (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More information can be found at: [www.iba-worldwide.com](http://www.iba-worldwide.com)



**For further information please contact:**

**IBA**

Olivier de Sadeleer  
Marketing Manager PT  
+32 10 475 960  
[Investorrelations@iba-group.com](mailto:Investorrelations@iba-group.com)

Thomas Ralet  
Vice-President Corporate Communication  
+32 10 475 890  
[communication@iba-group.com](mailto:communication@iba-group.com)

**For media and investor enquiries:**

**Consilium Strategic Communications**

Amber Bielecka, Mary-Jane Elliott, Matthew Neal  
+44 (0) 207 920 2333  
[IBA@consilium-comms.com](mailto:IBA@consilium-comms.com)